GSGabriela Leao Santos

Gabriela Leao Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriela Leao Santos has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Susanne Lutz

    Institute of Pharmacology and Toxicology (G.L.S., S.L., W.-H.Z.), University Medical Center Göttingen, Göttingen, Germany

    3 shared publications
  • Wolfram-Hubertus Zimmermann

    Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany

    2 shared publications
  • Abdul Rehman

    Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany

    1 shared publication
  • Alexandra Victoria Busley

    Departments of Cardiology and Pneumology (J.F., M.P.-G., F.K., A.V.B., A.F., R.H., G.H., L.C.), University Medical Center Göttingen, Göttingen, Germany

    1 shared publication
  • Alfredo Cabrera-Orefice

    Institute of Biochemistry, Faculty of Medicine, Justus Liebig University, Giessen, Germany

    1 shared publication
  • Alisa Fedorenko

    Departments of Cardiology and Pneumology (J.F., M.P.-G., F.K., A.V.B., A.F., R.H., G.H., L.C.), University Medical Center Göttingen, Göttingen, Germany

    1 shared publication

Latest Publications

  • Open Access

    Targeting Interleukin-8–Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome

    by Jakob Fell, Mario Pavez-Giani, Fabian Koitka, George Kensah, Gabriela Leao Santos, Emiel P.C. van der Vorst, Christof Lenz, Gabriela Salinas, Alexandra Victoria Busley, Alisa Fedorenko, et al.

    BACKGROUND: Genetic variants in components or regulators of the RAS-MAPK signaling pathway are causative for severe and early-onset hypertrophic cardiomyopathy (HCM) in patients with Noonan syndrome (NS). Despite paracrine communication being considered to play a pivotal role in the etiology of cardiomyopathies, there is a paucity of knowledge about the underlying pathomechanism that leads to the development of hypertrophic cardiomyopathy and cardiac fibrosis in NS. METHODS: To dissect the impact of noncardiomyocytes in the development of NS, we employed two-dimensional and three-dimensional human induced pluripotent stem cell models of LZTR1 deficiency alongside induced pluripotent stem cells derived from patients with NS with pathogenic variants in key RAS-MAPK genes and analyzed these cells and tissues at the molecular, cellular, and functional levels. RESULTS: Our findings revealed that cytokine-mediated cellular crosstalk between cardiac fibroblasts and cardiomyocytes, predominantly activated in the disease state, serves as a primary driver of the disease. Cardiac fibroblast–specific IL-8 (interleukin-8) secretion induced fibrosis-related signatures, tissue stiffness, cardiomyocyte hypertrophy, and hypercontractility, identifying dysregulated IL-8 as a heart-autonomous signaling molecule independent of inflammation and immune cell involvement. Inhibition of IL-8–CXCR1 signaling by reparixin reversed the pathological effects in cardiac fibroblasts and cardiomyocytes. CONCLUSIONS: These data provide evidence that targeting aberrant IL-8–CXCR1 signaling may be an effective therapeutic option for patients with NS-associated hypertrophic cardiomyopathy.


  • Open Access

    Enhancing KLF15 activity in cardiomyocytes: a novel approach to prevent pathological reprogramming and fibrosis via nuclease-deficient dCas9VPR

    by Eric Schoger, Rosa Kim, Federico Bleckwedel, Tomás M. Peralta, Laura Priesmeier, Janek A. Fischer, Laura Stengel, Cheila Rocha, Gabriela L. Santos, Susanne Lutz, et al.

    Transcriptional activity perturbation holds promise for selectively modulating harmful transcriptional networks, but its therapeutic potential remains largely unexplored. We employed a network-based analysis of single-cell heart transcriptomes to identify transcription factor activities linked to pathological cardiomyocytes in vivo. This analysis revealed that transcriptional activity of Krüppel-like factor 15 (KLF15) exhibited the most significant change in pathological cardiomyocytes, characterized by less effective repression of disease-associated genes in stressed hearts, which correlated with reduced KLF15 expression. To restore KLF15 activity, we utilized CRISPR/nuclease-dead (d)Cas9-based transcriptional enhancement (CRISPRa) in cardiomyocytes, which effectively abolished fetal reprogramming by simultaneously suppressing pathological gene expression and restoring metabolic homeostasis under sustained stress conditions. Furthermore, we identified a novel cell-nonautonomous anti-fibrotic effect mediated by cardiomyocyte-fibroblast crosstalk, and revealed the contribution of KLF15-dependent Alpha-2-glycoprotein 1, zinc-binding (AZGP1) regulation in this process. We also elucidated the upstream mechanisms of KLF15 regulation, highlighting its role as a cell-specific downstream target of the broad TGF-β canonical signaling pathway, along with its downstream-dependent mechanisms in human cardiomyocytes. Finally, to enhance the therapeutic potential of this approach, we engineered and validated an adeno-associated viral (AAV) vector with a small CRISPRa system for endogenous regulation in human cardiomyocytes suitable for clinical applications. Overall, we elucidated a regulatory circuit involving TGF-β, KLF15, and AZGP1, which coordinates critical pathological responses through cellular crosstalk between cardiomyocytes and fibroblasts. Importantly, we demonstrated the efficacy of CRISPRa as an epigenetic intervention restoring a critical transcriptional function disrupted in non-genetic heart failure. This approach provides a promising blueprint for future adaptation targeting additional non-hereditary pathologies.

  • Open Access

    Modulating the Biomechanical Properties of Engineered Connective Tissues by Chitosan-Coated Multiwall Carbon Nanotubes

    by Naim Kittana, Mohyeddin Assali, Wolfram-Hubertus Zimmermann, Norman Liaw, Gabriela Leao Santos, Abdul Rehman, Susanne Lutz

    Background: Under certain conditions, the physiological repair of connective tissues might fail to restore the original structure and function. Optimized engineered connective tissues (ECTs) with biophysical properties adapted to the target tissue could be used as a substitution therapy. This study aimed to investigate the effect of ECT enforcement by a complex of multiwall carbon nanotubes with chitosan (C-MWCNT) to meet in vivo demands. Materials and Methods: ECTs were constructed from human foreskin fibroblasts (HFF-1) in collagen type I and enriched with the three different percentages 0.025, 0.05 and 0.1% of C-MWCNT. Characterization of the physical properties was performed by biomechanical studies using unidirectional strain. Results: Supplementation with 0.025% C-MWCNT moderately increased the tissue stiffness, reflected by Young’s modulus, compared to tissues without C-MWCNT. Supplementation of ECTs with 0.1% C-MWCNT reduced tissue contraction and increased the elasticity and the extensibility, reflected by the yield point and ultimate strain, respectively. Consequently, the ECTs with 0.1% C-MWCNT showed a higher resilience and toughness as control tissues. Fluorescence tissue imaging demonstrated the longitudinal alignment of all cells independent of the condition. Conclusion: Supplementation with C-MWCNT can enhance the biophysical properties of ECTs, which could be advantageous for applications in connective tissue repair.